troglitazone has been researched along with Liver Failure in 16 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data from cases of liver failure associated with troglitazone use were abstracted and analyzed." | 7.72 | Troglitazone-induced liver failure: a case study. ( Graham, DJ; Green, L; Nourjah, P; Senior, JR, 2003) |
| "Troglitazone may cause subfulminant liver failure." | 7.70 | Troglitazone-induced hepatic failure leading to liver transplantation. A case report. ( Brunt, EM; Isley, WL; Neuschwander-Tetri, BA; Oki, JC; Phillips, NJ; Quiason, SG; Ramrakhiani, S, 1998) |
| "An autopsy case of fatal subacute hepatic failure after administration of troglitazone is described." | 7.70 | Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. ( Adachi, H; Amano, S; Bamba, T; Fujiyama, Y; Fukano, M; Okabe, H; Sato, J; Yamamoto, K, 2000) |
| "Data from cases of liver failure associated with troglitazone use were abstracted and analyzed." | 3.72 | Troglitazone-induced liver failure: a case study. ( Graham, DJ; Green, L; Nourjah, P; Senior, JR, 2003) |
| "Troglitazone may cause subfulminant liver failure." | 3.70 | Troglitazone-induced hepatic failure leading to liver transplantation. A case report. ( Brunt, EM; Isley, WL; Neuschwander-Tetri, BA; Oki, JC; Phillips, NJ; Quiason, SG; Ramrakhiani, S, 1998) |
| "An autopsy case of fatal subacute hepatic failure after administration of troglitazone is described." | 3.70 | Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. ( Adachi, H; Amano, S; Bamba, T; Fujiyama, Y; Fukano, M; Okabe, H; Sato, J; Yamamoto, K, 2000) |
| "Troglitazone is a useful new oral antihyperglycemic agent, but in about 1." | 2.41 | Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. ( Banner, BF; Bonkovsky, HL; Kohlroser, J; Mathai, J; Reichheld, J, 2000) |
| "Troglitazone (TGZ) is an orally active hypoglycemic agent which is used for the treatment of non-insulin-dependent diabetes mellitus." | 1.36 | Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. ( Chan, EC; Chui, WK; Ho, HK; New, LS; Saha, S, 2010) |
| "Troglitazone was approved for treatment of type 2 diabetes mellitus, but by 2000 it had been removed from all world markets due to severe drug-induced liver injury." | 1.35 | Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone. ( Julie, IM; Julie, NL; Kende, AI; Wilson, GL, 2008) |
| "Acute liver failure was defined as acute liver disease and (1) hepatic encephalopathy, (2) prothrombin time prolongation greater than 3 seconds or international normalized ratio greater than 1." | 1.32 | A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. ( Ackerson, L; Chan, KA; Everhart, JE; Gurwitz, JH; Hurley, JS; Martinson, B; Moseley, RH; Platt, R; Selby, JV; Terrault, N; Truman, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Julie, NL | 1 |
| Julie, IM | 1 |
| Kende, AI | 1 |
| Wilson, GL | 1 |
| Saha, S | 1 |
| New, LS | 1 |
| Ho, HK | 1 |
| Chui, WK | 1 |
| Chan, EC | 1 |
| Chan, KA | 1 |
| Truman, A | 1 |
| Gurwitz, JH | 1 |
| Hurley, JS | 1 |
| Martinson, B | 1 |
| Platt, R | 1 |
| Everhart, JE | 1 |
| Moseley, RH | 1 |
| Terrault, N | 1 |
| Ackerson, L | 1 |
| Selby, JV | 1 |
| Graham, DJ | 1 |
| Green, L | 1 |
| Senior, JR | 1 |
| Nourjah, P | 1 |
| Watkins, PB | 1 |
| Whitcomb, RW | 1 |
| Neuschwander-Tetri, BA | 1 |
| Isley, WL | 1 |
| Oki, JC | 1 |
| Ramrakhiani, S | 1 |
| Quiason, SG | 1 |
| Phillips, NJ | 1 |
| Brunt, EM | 1 |
| Miller, JL | 2 |
| Kohlroser, J | 1 |
| Mathai, J | 1 |
| Reichheld, J | 1 |
| Banner, BF | 1 |
| Bonkovsky, HL | 1 |
| Fukano, M | 1 |
| Amano, S | 1 |
| Sato, J | 1 |
| Yamamoto, K | 1 |
| Adachi, H | 1 |
| Okabe, H | 1 |
| Fujiyama, Y | 1 |
| Bamba, T | 1 |
| Booth, AM | 1 |
| Caldwell, SH | 1 |
| Iezzoni, JC | 1 |
| Murphy, EJ | 1 |
| Davern, TJ | 1 |
| Shakil, AO | 1 |
| Shick, L | 1 |
| Masharani, U | 1 |
| Chow, H | 1 |
| Freise, C | 1 |
| Lee, WM | 1 |
| Bass, NM | 1 |
| Greene, HL | 1 |
| Gale, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Trial to Study Acute Liver Failure in Adults[NCT00518440] | 3,488 participants (Actual) | Observational | 1998-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for troglitazone and Liver Failure
| Article | Year |
|---|---|
Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Liver Failure; Male | 2000 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes | 2001 |
14 other studies available for troglitazone and Liver Failure
| Article | Year |
|---|---|
Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone.
Topics: Adult; Aged; Biopsy; Chromans; Female; Humans; Hypoglycemic Agents; Liver; Liver Failure; Male; Midd | 2008 |
Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Topics: Cell Line; Cell Survival; Chromans; Drug Stability; Glutathione; Hepatocytes; Humans; Hypoglycemic A | 2010 |
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.
Topics: Acute Disease; Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; Cohort Studies; Female | 2003 |
Troglitazone-induced liver failure: a case study.
Topics: Age Distribution; Aged; Chemical and Drug Induced Liver Injury; Chromans; Chronic Disease; Confidenc | 2003 |
Insight into hepatotoxicity: The troglitazone experience.
Topics: Chromans; Humans; Hypoglycemic Agents; Liver; Liver Failure; Thiazolidinediones; Troglitazone | 2005 |
Update in endocrinology.
Topics: Chromans; Humans; Hypoglycemic Agents; Liver Failure; Neutropenia; Thiazoles; Thiazolidinediones; Tr | 1998 |
Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Trans | 1998 |
FDA drug-review, surveillance processes under scrutiny.
Topics: Chromans; Drug Approval; Humans; Hypoglycemic Agents; Liver Failure; Product Surveillance, Postmarke | 1999 |
Advisory panel hears contradictory evidence, backs keeping troglitazone on market.
Topics: Chromans; Consultants; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Failure; Thiazoles; Thiaz | 1999 |
Diabetes drug Rezulin: take it, but take precautions.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Test | 1999 |
Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
Topics: Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Humans; Hypoglycemic Agents; Liver Failu | 2000 |
Troglitazone-associated hepatic failure.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Fe | 2000 |
Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Liver Failure; Midd | 2000 |
Drug recalls underscore safety concerns.
Topics: Arrhythmias, Cardiac; Chromans; Cisapride; Drug and Narcotic Control; Gastrointestinal Agents; Human | 2000 |